ERCC1 and osteosarcoma: Fanelli et al. (2020) used the in vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatment in cisplatin-resistant osteosarcoma and found the ERCC1 gene as one of the main therapeutic targets [28].